AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
PHASE1
This is an open-label, Phase 1/2, multicenter study to evaluate the safety,...
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
PHASE1
In order to improve the survival rates and decrease progression of pancreat...
A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
PHASE1
This is a Phase 1/2, open-label study of zalifrelimab (AGEN1884) in combina...